At BioAI, our mission is to deliver cancer tests that improve patient outcomes and save lives.



Our vision starts with lung cancer. AI-powered predictive tests can reduce the time and expense required to identify the best therapy for patients.



We are a seasoned team of digital pathology/AI industry experts with 30+ years of experience from development through commercialization, so we know which questions to ask, how to build solutions, and how to implement them.



Our approach is unique, leveraging multimodal data, pathology, genomics, and real-world evidence alongside the latest AI/ML technologies. We focus on causal biology to understand morphology, enabling us to deliver the highest-quality predictive biomarkers for clinical development and/or patient identification in early diagnostic testing.